Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 20/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12092610 | 0.83 | AKR1B1 (0.48) | AKR1B1 | |
| SCHEMBL1106721 | 0.81 | SMN1; SMN2 (0.40) | AKR1B1 | |
| SCHEMBL23871106 | 0.81 | AKR1B1 (0.43) | AKR1B1 | |
| SCHEMBL14502205 | 0.81 | AKR1B1 (0.43) | AKR1B1 | |
| SCHEMBL23158365 | 0.80 | AKR1B1 (0.35) | AKR1B1 | |
| SCHEMBL23733915 | 0.80 | AKR1B1 (0.44) | AKR1B1 | |
| SCHEMBL24658619 | 0.80 | AKR1B1 (0.33) | AKR1B1 | |
| SCHEMBL22950788 | 0.80 | AKR1B1 (0.44) | AKR1B1 | |
| SCHEMBL10264375 | 0.77 | SMN1; SMN2 (0.36) | AKR1B1 | |
| SCHEMBL22951183 | 0.75 | AKR1B1 (0.32) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4003314-B1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS USEFUL FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS INC (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-4327887-A2 | FIXED DOSE COMBINATIONS AND FORMULATIONS COMPRISING ETC1002 AND ONE OR MORE STATINS AND METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE | Esperion Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3270909-B1 | FIXED DOSE COMBINATIONS COMPRISING ETC1002 AND ONE OR MORE STATINS FOR TREATING OR REDUCING CARDIOVASCULAR RISK | ESPERION THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230278952-A1 | Compounds Useful for Treating Liver Diseases | ABIONYX PHARMA SA (FR) | 2023-09-07 | — | — | US | disclosed |
| US-11744816-B2 | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease | ESPERION THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11744816-B2 | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease | ESPERION THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230210800-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20220363632-A1 | Compounds Useful for Treating Liver Diseases | ABIONYX PHARMA SA (FR) | 2022-11-17 | — | — | US | disclosed |
| WO-2022189856-A9 | COMPOUNDS USEFUL FOR TREATING LIVER DISEASES | ABIONYX PHARMA SA (FR) | 2022-10-13 | — | — | WO | disclosed |
| US-20210395175-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2021-12-23 | — | — | US | disclosed |
| EP-1862444-A2 | Ether compounds, compositions, and uses thereof | Esperion Therapeutics, Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| US-7304093-B2 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304093-B2 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| EP-1849760-A1 | Ether compounds, compositions, and uses thereof | Esperion Therapeutics Inc. (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20070179120-A1 | administering to a patient a hydroxy compound to treat aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, septicemia and syndrome X | ESPERION THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070179120-A1 | administering to a patient a hydroxy compound to treat aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, septicemia and syndrome X | ESPERION THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070155704-A1 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155704-A1 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070149615-A9 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | DASSEUX JEAN-LOUIS H | 2007-06-28 | — | — | US | disclosed |
| US-20070149615-A9 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | DASSEUX JEAN-LOUIS H | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278952-A1 | Compounds Useful for Treating Liver Diseases | SLC10A1, FABP1, CPT1A | AKR1B1 4/4885 |
| US-11744816-B2 | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease | APOB, PCSK9, GOT2 | AKR1B1 321/4885 |
| US-20210395175-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | NR1H3, CYP27A1, NR1H2 | AKR1B1 200/4885 |
| US-20070155704-A1 | Ketone compounds and compositions for cholesterol management and related uses | PC, HMGCR, GPR119 | AKR1B1 48/4885 |
| US-20230210800-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | CYP27A1, NR1H3, PNLIP | AKR1B1 156/4885 |
| US-20070179120-A1 | administering to a patient a hydroxy compound to treat aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, septicemia and syndrome X | PNLIP, NR1H3, CYP27A1 | AKR1B1 258/4885 |
| US-20220363632-A1 | Compounds Useful for Treating Liver Diseases | SLC10A1, FABP1, CPT1A | AKR1B1 4/4885 |
| US-20070149615-A9 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PC, HMGCR, GPR119 | AKR1B1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.